Prostate-specific membrane antigen (PSMA) targeting radionuclide therapy (RNT) in combination with anti-PD-1 has also shown promising therapeutic results in a mouse model of PCa (C57BL/6-mice bearing syngeneic RM1-PGLS tumour) [126,127]. The gene discussed is FOLH1; the disease is neoplasm.